Chronic Myeloid Leukemia Coverage From Every Angle

Recent News

Controlling Graft-vs-Host Disease in Older Patients After Stem Cell Transplantation
Use of Risk Stratification Scores in Elderly Patients With CML
First-Line Nilotinib Treatment In Newly Diagnosed CML
TKI Resistance and Compound BCR-ABL1 Kinase Domain Mutations in Leukemia
Novel Therapeutic Strategy May Improve Treatment Efficacy Against Leukemia
ASH 2018: 5-Year Analysis of Imatinib vs. Dasatinib in Newly Diagnosed Chronic Phase CML
ASH 2018: Making the Decision to Switch to Dasatinib From Imatinib in CML
ASH 2018: Intermittent TKI Therapy in Elderly Patients With CML
ASH 2018: Might Asciminib Become a New Treatment Option in CML?
ASH 2018: Is Generic Imatinib as Effective as Its Brand Counterpart in Chronic Phase CML?
ASH 2018: Cardiovascular Events Associated With Ponatinib Treatment of CML
Rare Case of CML After Transplantation in Patient With Multiple Myeloma
FDA Grants Priority Review to Ruxolitinib for Acute Graft-Versus-Host-Disease
ESMO 2018: Bosutinib vs. Imatinib in Indian and Non-Indian Patients With CML
ESMO 2018: Nurse-Led Approach to Monitor Use of Oral Treatments in CML
Bone Morphogenic Protein Pathway Essential for CML Cells
ESMO 2018: Compound Mutations and Response to Therapy With Tyrosine Kinase Inhibitors
FDA Offers Draft Guidance on Use of MRD in Hematologic Malignancies
Case Report of Elevated Intracranial Pressure in Patient With CML
Cancer Research UK Grants Funding to University of Glasgow for CML Research
Novel Approach to Restoring Beneficial Gut Bacteria After HCT
Nilotinib and Dasatinib Go Head-to-Head in Retrospective CML Study
Quantitative Methods to Evaluate Imatinib Versus Dasatinib Response in CML
Treatment Strategies for Older Patients With Chronic Myeloid Leukemia
Rare Case of b3a3 (e14a3) Fusion in Chronic Myeloid Leukemia Reported
Are Endothelial Cells the Key to Predicting Vascular Toxicity of TKIs?
Treatment-Free Remission and 2-Year Nilotinib Consolidation in CML
FDA Issues Warning About Long-Term Use of Azithromycin After Donor Stem Cell Transplant
Ponatinib REMS Program No Longer Required, FDA Says
After Suboptimal Response to Imatinib, What’s Next for Patients With CML?
Rare Case of Patient With Gaucher Disease and CML Reported in Spain

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.